Anti-Mouse VEGF Antibody (G6-31)

Anti-Mouse VEGF Antibody (G6-31) 是一种抗小鼠 VEGF 抗体,可阻断 VEGF-A 介导的血管生成并具有抗肿瘤活性,可用于癌症研究,例如 1 型多发性内分泌腺瘤。
Anti-Mouse VEGF Antibody (G6-31)
产品编号: MS-Y88915
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

Anti-Mouse VEGF Antibody (G6-31) 是一种抗小鼠 VEGF 抗体,可阻断 VEGF-A 介导的血管生成并具有抗肿瘤活性,可用于癌症研究,例如 1 型多发性内分泌腺瘤。

生物实验数据

生物活性 Anti-Mouse VEGF Antibody (G6-31) is an anti-mouse VEGF antibody that blocks VEGF-A-mediated angiogenesis and exhibits antitumor activity, and can be used in cancer research, such as type 1 multiple endocrine neoplasia.
体内研究
(In Vivo)

Anti-Mouse VEGF Antibody (G6-31) (5 mg/kg;腹腔注射;每周 1 次;持续 67 天) 可使自发性垂体腺瘤的 Men1+/-小鼠的平均垂体腺瘤体积减少 72%,延长无肿瘤倍增生存期,降低血清催乳素水平,并降低肿瘤血管密度。
Anti-Mouse VEGF Antibody (G6-31) (5 mg/kg;腹腔注射;每周 1 次;持续 35 天) 可使 BALB/c 裸鼠皮下垂体腺瘤移植瘤体积减少 73%,并降低其血清催乳素水平。

Animal Model: Men1+/-
mice (female, mixed 129-FVB background, 13.5 to 14.5 months of age, spontaneous pituitary adenomas)
Dosage: 5 mg/kg
Administration: i.p.; once weekly; 67 days
Result: Reduced mean pituitary adenoma volume by 72% at day 67.
Increased tumor doubling-free survival, with 2 of 8 mice showing no tumor doubling by day 67.
Reduced mean serum prolactin level to 5,163.7 ± 1,608.9 ng/mL at study end point, a significant decrease compared to control.
Reduced pituitary tumor vascular density to 46% of control levels.
Significantly elevated mean relative expression of VEGF-A in treated tumors.
Significantly lowered mean expression levels of VEGFR-1, VEGFR-2, CD31, and Tie-2 compared to control.
Animal Model: BALB/c nude (female, 6 to 8 weeks old at grafting, treated 4 months post-grafting, subcutaneous grafted Men1+/- pituitary adenomas)
Dosage: 5 mg/kg
Administration: i.p.; once weekly; 35 days
Result: Reduced mean subcutaneous tumor volume by 73% at day 35 (P < 0.0001); mean tumor volume remained stable at 556 ± 89 mm3 compared to a quadrupling of volume in controls.
Significantly reduced serum prolactin levels at day 35 compared to control, while levels were comparable between groups at treatment onset.

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础